Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting ...
An investigational anti-clotting medication, asundexian, has demonstrated a reduction in the risk of a second ischemic ...
Eleven top scientists in stroke and brain health will be recognized for their individual exceptional professional achievements and contributions to stroke and brain health care and research during the ...
News-Medical.Net on MSN
Investigational anti-clotting drug reduces risk of second ischemic stroke without bleeding concerns
An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic ...
For patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack, asundexian, a factor XIa inhibitor ...
Eleven top scientists in stroke and brain health will be recognized for their individual exceptional professional ...
Late-Breaking Science Abstract LB 032 - In a phase III clinical trial in China, stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days starting ...
The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...
The American Heart Association and American Stroke Association have issued an updated guideline for the diagnosis and treatment of acute ischemic stroke.The new guideline, published in Stroke, ...
A new predictive tool may help identify patients at risk for poststroke dementia, potentially accelerating research and ...
Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, announces the launch of its ...
UC experts present stroke research at the International Stroke Conference 2026, discussing post-stroke disability predictors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results